Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck invests in biologics

September 4, 2006 | A version of this story appeared in Volume 84, Issue 36

Germany's Merck will invest roughly $240 million in a biopharmaceutical plant in Darmstadt, Germany. The facility, expected to open in 2010, will manufacture biological active ingredients for the treatment of cancer. Initially, the site will be primarily dedicated to the production of Erbitux, the ImClone Systems monoclonal antibody that Merck markets outside of the U.S. The project will result in about 190 new jobs. The investment is a shift in strategy for Merck, which in 2003 abandoned plans to build a biologics plant in Jena, Germany, in favor of buying Erbitux from Boehringer Ingelheim and ImClone. Erbitux has since become Merck's top-selling drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.